Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867

Alex Dayton, Karuppaiyah Selvendiran, Sarath Meduru, Mahmood Khan, M. Lakshmi Kuppusamy, Shan Naidu, T. Kalai, K. Hideg, Periannan Kuppusamy

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Doxorubicin (DOX) is a drug commonly used for the treatment of cancer. The development of resistance to DOX is common, and high cumulative doses cause potentially lethal cardiac side effects. HO-3867 (3,5-bis(4-fluorobenzylidene)- 1-[(2,2,5,5-tetramethyl- 2,5-dihydro-1-hydroxy-pyrrol-3-yl)methyl]piperidin-4- one), a synthetic curcumin analog, has been shown to exhibit both anticancer and cardioprotective effects. However, its cardioprotection in the setting of a conventional cancer therapy has not been established. This work investigated the use of HO- 3867 and DOX to achieve a complementary outcome, i.e., increased toxicity toward cancer cells, and reduced cardiac toxicity. Combination treatment was investigated using DOXresistant MCF-7 breast cancer cells [MCF-7 multidrug-resistant (MDR)] and BALB/c mice. Lower doses of HO-3867 and DOX (5 and 2.5 μM, respectively) reduced viability of MCF-7 MDR cells to an extent significantly greater than that when either drug was used alone, an effect equivalent to that induced by exposure to 50 μM DOX. In normal cardiac cells, the loss of viability from combination treatment was significantly lower than that induced by 50 μM DOX. Increases in apoptotic markers, e.g., cleaved caspase-3, and decreases in fatty acid synthase and pAkt expressions were observed by Western blotting. Mice treated with both HO-3867 and DOX showed significant improvement in cardiac functional parameters compared with mice treated with DOX alone. Reduced expression of Bcl-2 and pAkt was observed in mice treated with DOX alone, whereas mice given combination treatment showed levels similar to control. The study indicates that combination treatment of HO- 3867 and DOX is a viable option for treatment of cancer with reduced cardiotoxic side effects.

Original languageEnglish
Pages (from-to)350-357
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume339
Issue number2
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Doxorubicin
Antioxidants
Neoplasms
(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one)
Cardiotoxicity
Fatty Acid Synthases
Curcumin
MCF-7 Cells
Caspase 3
Pharmaceutical Preparations
Cell Survival
Western Blotting
Breast Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867. / Dayton, Alex; Selvendiran, Karuppaiyah; Meduru, Sarath; Khan, Mahmood; Kuppusamy, M. Lakshmi; Naidu, Shan; Kalai, T.; Hideg, K.; Kuppusamy, Periannan.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 339, No. 2, 11.2011, p. 350-357.

Research output: Contribution to journalArticle

Dayton, Alex ; Selvendiran, Karuppaiyah ; Meduru, Sarath ; Khan, Mahmood ; Kuppusamy, M. Lakshmi ; Naidu, Shan ; Kalai, T. ; Hideg, K. ; Kuppusamy, Periannan. / Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867. In: Journal of Pharmacology and Experimental Therapeutics. 2011 ; Vol. 339, No. 2. pp. 350-357.
@article{0815878aa7ef4adb9c15a0fde47b2b17,
title = "Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867",
abstract = "Doxorubicin (DOX) is a drug commonly used for the treatment of cancer. The development of resistance to DOX is common, and high cumulative doses cause potentially lethal cardiac side effects. HO-3867 (3,5-bis(4-fluorobenzylidene)- 1-[(2,2,5,5-tetramethyl- 2,5-dihydro-1-hydroxy-pyrrol-3-yl)methyl]piperidin-4- one), a synthetic curcumin analog, has been shown to exhibit both anticancer and cardioprotective effects. However, its cardioprotection in the setting of a conventional cancer therapy has not been established. This work investigated the use of HO- 3867 and DOX to achieve a complementary outcome, i.e., increased toxicity toward cancer cells, and reduced cardiac toxicity. Combination treatment was investigated using DOXresistant MCF-7 breast cancer cells [MCF-7 multidrug-resistant (MDR)] and BALB/c mice. Lower doses of HO-3867 and DOX (5 and 2.5 μM, respectively) reduced viability of MCF-7 MDR cells to an extent significantly greater than that when either drug was used alone, an effect equivalent to that induced by exposure to 50 μM DOX. In normal cardiac cells, the loss of viability from combination treatment was significantly lower than that induced by 50 μM DOX. Increases in apoptotic markers, e.g., cleaved caspase-3, and decreases in fatty acid synthase and pAkt expressions were observed by Western blotting. Mice treated with both HO-3867 and DOX showed significant improvement in cardiac functional parameters compared with mice treated with DOX alone. Reduced expression of Bcl-2 and pAkt was observed in mice treated with DOX alone, whereas mice given combination treatment showed levels similar to control. The study indicates that combination treatment of HO- 3867 and DOX is a viable option for treatment of cancer with reduced cardiotoxic side effects.",
author = "Alex Dayton and Karuppaiyah Selvendiran and Sarath Meduru and Mahmood Khan and Kuppusamy, {M. Lakshmi} and Shan Naidu and T. Kalai and K. Hideg and Periannan Kuppusamy",
year = "2011",
month = "11",
doi = "10.1124/jpet.111.183681",
language = "English",
volume = "339",
pages = "350--357",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867

AU - Dayton, Alex

AU - Selvendiran, Karuppaiyah

AU - Meduru, Sarath

AU - Khan, Mahmood

AU - Kuppusamy, M. Lakshmi

AU - Naidu, Shan

AU - Kalai, T.

AU - Hideg, K.

AU - Kuppusamy, Periannan

PY - 2011/11

Y1 - 2011/11

N2 - Doxorubicin (DOX) is a drug commonly used for the treatment of cancer. The development of resistance to DOX is common, and high cumulative doses cause potentially lethal cardiac side effects. HO-3867 (3,5-bis(4-fluorobenzylidene)- 1-[(2,2,5,5-tetramethyl- 2,5-dihydro-1-hydroxy-pyrrol-3-yl)methyl]piperidin-4- one), a synthetic curcumin analog, has been shown to exhibit both anticancer and cardioprotective effects. However, its cardioprotection in the setting of a conventional cancer therapy has not been established. This work investigated the use of HO- 3867 and DOX to achieve a complementary outcome, i.e., increased toxicity toward cancer cells, and reduced cardiac toxicity. Combination treatment was investigated using DOXresistant MCF-7 breast cancer cells [MCF-7 multidrug-resistant (MDR)] and BALB/c mice. Lower doses of HO-3867 and DOX (5 and 2.5 μM, respectively) reduced viability of MCF-7 MDR cells to an extent significantly greater than that when either drug was used alone, an effect equivalent to that induced by exposure to 50 μM DOX. In normal cardiac cells, the loss of viability from combination treatment was significantly lower than that induced by 50 μM DOX. Increases in apoptotic markers, e.g., cleaved caspase-3, and decreases in fatty acid synthase and pAkt expressions were observed by Western blotting. Mice treated with both HO-3867 and DOX showed significant improvement in cardiac functional parameters compared with mice treated with DOX alone. Reduced expression of Bcl-2 and pAkt was observed in mice treated with DOX alone, whereas mice given combination treatment showed levels similar to control. The study indicates that combination treatment of HO- 3867 and DOX is a viable option for treatment of cancer with reduced cardiotoxic side effects.

AB - Doxorubicin (DOX) is a drug commonly used for the treatment of cancer. The development of resistance to DOX is common, and high cumulative doses cause potentially lethal cardiac side effects. HO-3867 (3,5-bis(4-fluorobenzylidene)- 1-[(2,2,5,5-tetramethyl- 2,5-dihydro-1-hydroxy-pyrrol-3-yl)methyl]piperidin-4- one), a synthetic curcumin analog, has been shown to exhibit both anticancer and cardioprotective effects. However, its cardioprotection in the setting of a conventional cancer therapy has not been established. This work investigated the use of HO- 3867 and DOX to achieve a complementary outcome, i.e., increased toxicity toward cancer cells, and reduced cardiac toxicity. Combination treatment was investigated using DOXresistant MCF-7 breast cancer cells [MCF-7 multidrug-resistant (MDR)] and BALB/c mice. Lower doses of HO-3867 and DOX (5 and 2.5 μM, respectively) reduced viability of MCF-7 MDR cells to an extent significantly greater than that when either drug was used alone, an effect equivalent to that induced by exposure to 50 μM DOX. In normal cardiac cells, the loss of viability from combination treatment was significantly lower than that induced by 50 μM DOX. Increases in apoptotic markers, e.g., cleaved caspase-3, and decreases in fatty acid synthase and pAkt expressions were observed by Western blotting. Mice treated with both HO-3867 and DOX showed significant improvement in cardiac functional parameters compared with mice treated with DOX alone. Reduced expression of Bcl-2 and pAkt was observed in mice treated with DOX alone, whereas mice given combination treatment showed levels similar to control. The study indicates that combination treatment of HO- 3867 and DOX is a viable option for treatment of cancer with reduced cardiotoxic side effects.

UR - http://www.scopus.com/inward/record.url?scp=80054790399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054790399&partnerID=8YFLogxK

U2 - 10.1124/jpet.111.183681

DO - 10.1124/jpet.111.183681

M3 - Article

VL - 339

SP - 350

EP - 357

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -